Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304173 · ClinicalTrials.gov registry record
Retrospective Chart Review of Valstar
A clinical trial of Carcinoma in Situ of Bladder, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- 113
- Enrollment target
- 1
- Study location
NCT01304173 is a study of Carcinoma in Situ of Bladder that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 113 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01304173, a study of Carcinoma in Situ of Bladder, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01304173
The ClinicalTrials.gov registry entry for NCT01304173 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma in Situ of Bladder appearing as the primary indexed condition, and to 0 interventions.
NCT01304173 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01304173 about?
NCT01304173 is a clinical study titled "Retrospective Chart Review of Valstar". This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
What is the current status of trial NCT01304173?
This trial is currently completed. The enrollment target is 113 participants. The study started on 2011-03. Estimated completion is 2011-10.
What conditions does trial NCT01304173 study?
This clinical trial studies the following conditions: Carcinoma in Situ of Bladder.
Who is sponsoring clinical trial NCT01304173?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01304173 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.